Advice - reimburse atogepant (Aquipta®) for the treatment of migraine
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse atogepant (Aquipta®) from the basic health care package. This medicinal product can be used in certain patients with migraine. If the minister adopts our advice, atogepant will be included in the Medicine Reimbursement System (GVS). Only then will this medicinal product be reimbursed from the health care insurer's basic health care package.
Current state of affairs: advisory report sent to the Minister
The National Health Care Institute has sent this advice to the Minister of VWS. The Minister makes the final decision whether or not to reimburse the medicinal product from the basic health care package.
Atogepant is intended for certain people with migraine
Atogepant is the active substance. The brand name is Aquipta®. The medicinal product is a tablet that is swallowed daily. The medicinal product is a CGRP inhibitor, as are erenumab, fremanezumab and galcanezumab. However, those three medicinal products are administered differently, with an injection under the skin.
The medicinal product can be used in people with migraine who have at least 4 migraine days per month. People with migraine suffer from headache attacks.
Advice from the National Health Care Institute on the reimbursement of atogepant
The National Health Care Institute advises the Minister of WVS to reimburse atogepant (Aquipta®) from the basic health care package. The advice is to include the medicinal product in List 1B of the GVS. The National Health Care Institute also advises to reimburse atogepant under the same additional conditions and with agreements on appropriateness, as already apply to 3 other CGRP inhibitors: erenumab, fremanezumab and galcanezumab.
For more information on the GVS and the Lists 1A, 1B and 2, see page ‘Reimbursement of extramural drugs (GVS)’.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicinal product, the personal expenses or whether you should pay a contribution, please ask your health insurance provider.
How did the advice come about?
The Scientific Advisory Board (WAR) advises the National Health Care Institute about the assessment. The Minister makes the final decision whether or not to reimburse the medication from the basic health care package.
Explanation about the reimbursement of medicinal products
Atogepant is an outpatient drug. Outpatient means: medicines for home use that can be obtained at the pharmacy with the prescription from a physician. They are only reimbursed from the basic health care package if they are listed in the GVS.